Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed wins Israeli patent for core delivery technology
The patent covers a central facet of the company’s core technology in oral delivery of proteins. Oramed CEO Nadav Kidron said the Israeli patent covers a fundamental aspect
The patent covers a central facet of the company’s core technology in oral delivery of proteins. Oramed CEO Nadav Kidron said the Israeli patent covers a fundamental aspect
Following the acquisition of DRG, Piramal will operate DRG as a stand-alone business while retaining its headquarters in Burlington, US. The transaction is likely to close by 30
Atorvastatin (lipitor) is used for the treatment of high cholesterol and prevention of heart attack. The drug was launched in all the strengths including 10mg, 20mg, 40mg and
The 20-year term patent titled, Biocatalytic Processes For The Preparation Of Substantially Stereomerically Pure Fused Bicyclic Proline Compounds, does not expire until 2029. Codexis senior vice president Peter
The stabilized PTH formulations incorporate Aegis’ Intravail/ProTek excipients suitable for all routes of administration. Intravail and ProTek excipients allow for non-invasive delivery with high efficiency and stabilize, prevent
CytoFeline is a monoclonal antibody developed for the treatment of Feline Immunodeficiency Virus (FIV). Up on the completion of antibody purification, CVM will determine the practicality of anti-LFA1
RapidFire is in-line solid phase extraction technology which enables ultrafast, direct analysis of native compounds for a variety of biochemical assays. The Hamburg facility will be equipped with
Under the agreement, the companies will make the technology available to third parties and share in the revenue. The terms of the agreement were kept confidential. Avalanche chief
The investigational agent (tivozanib) has demonstrated statistically significant and clinically meaningful progression-free survival (PFS) superiority versus an approved targeted agent (sorafenib) in advanced RCC. AVEO Oncology president and
The Field ImpACT application integrates with Veeva System’s Customer Relationship Management (CRM) platform to create capabilities for Pharma sales operations and field forces. Model N’ s solution is